Share Price and Basic Stock Data
Last Updated: January 9, 2026, 7:56 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cian Healthcare Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹13.5 Cr and a share price of ₹5.39. The company has shown fluctuating revenue trends over recent years, with sales recording ₹69 Cr in FY 2023, down from ₹78 Cr in FY 2022. The most recent quarterly sales for September 2023 stood at ₹33 Cr, reflecting a slight recovery compared to ₹31 Cr in March 2023. However, the forecast for FY 2025 indicates a decline in projected sales to ₹31 Cr. This inconsistent performance highlights a challenging market environment, potentially influenced by increased competition and operational inefficiencies. The operating profit margin (OPM) has been volatile, with the latest reported OPM at -8% for September 2024, indicating significant operational challenges. Overall, while the company has potential, its revenue trends reveal a need for strategic adjustments to enhance growth and stabilize earnings.
Profitability and Efficiency Metrics
Cian Healthcare’s profitability metrics illustrate a struggle to maintain consistent earnings. The company reported a net profit of -₹26 Cr in FY 2025, down from a net profit of ₹2 Cr in FY 2023, demonstrating a concerning trend. The operating profit margin peaked at 22% in March 2023 but has since declined to 14% in September 2023 and is expected to fall to -8% by September 2024. The interest coverage ratio (ICR) was recorded at 1.95x, indicating that the company’s earnings are barely sufficient to cover interest expenses. The cash conversion cycle (CCC) stood at 235.85 days, reflecting inefficiencies in managing inventory and receivables. The return on equity (ROE) was reported at 30.3%, which is relatively strong, yet the return on capital employed (ROCE) at 10.6% suggests that the company is not optimally utilizing its capital. These figures reflect a pressing need for operational improvements to enhance profitability and overall financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Cian Healthcare reveals a leveraged position, with total borrowings amounting to ₹55 Cr against reserves of ₹7 Cr. This indicates a debt-to-equity ratio of 0.96x, suggesting a high reliance on debt financing. The current ratio is reported at 1.09x, which is marginally above the generally acceptable level of 1. This indicates that the company is capable of meeting its short-term obligations but remains on the brink of liquidity concerns. The book value per share is ₹23.10, while the price-to-book value ratio stands at 0.89x, suggesting that the stock is undervalued relative to its book value. However, the working capital days have improved to 26.27 days from 40.66 days in FY 2023, indicating a positive trend in managing short-term assets and liabilities. Overall, while the balance sheet shows some strengths, the high leverage remains a risk factor that could impact financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cian Healthcare reveals a significant shift in ownership. Promoters hold 27.11% of the company, a sharp decline from 70.89% in September 2021, indicating a reduced confidence from the founding members. The public shareholding has increased to 72.89%, suggesting that retail investors are becoming more prominent stakeholders, with the number of shareholders rising to 1,662 as of September 2025. However, the absence of Foreign Institutional Investors (FIIs) and a negligible stake from Domestic Institutional Investors (DIIs) may reflect a lack of institutional confidence in the company’s prospects. This shift in ownership dynamics could impact future capital raising efforts and strategic direction. The declining promoter stake, coupled with increasing public ownership, raises questions about the company’s governance and long-term strategy, which could further influence investor sentiment.
Outlook, Risks, and Final Insight
Cian Healthcare faces several risks that could hinder its recovery and growth trajectory. The company’s declining revenue and profitability metrics, coupled with high leverage, indicate vulnerabilities that management must address. Operational inefficiencies reflected in the cash conversion cycle and fluctuating profit margins present significant challenges. However, the high return on equity is a positive indicator of potential, suggesting that, with improved management and operational strategies, the company could enhance its performance. The outlook hinges on Cian Healthcare’s ability to streamline operations, manage costs effectively, and regain investor confidence, especially among institutional investors. A focus on sustainable growth strategies could position the company favorably in the competitive pharmaceuticals landscape, but it must navigate current challenges to achieve long-term stability and profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,259 Cr. | 391 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.9 Cr. | 39.5 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,294.49 Cr | 1,133.13 | 52.77 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 28 | 39 | 35 | 47 | 31 | 38 | 31 | 33 | 62 | 19 |
| Expenses | 26 | 23 | 34 | 28 | 44 | 30 | 32 | 24 | 28 | 51 | 20 |
| Operating Profit | 3 | 4 | 5 | 7 | 3 | 1 | 5 | 7 | 4 | 11 | -1 |
| OPM % | 10% | 15% | 13% | 20% | 7% | 3% | 14% | 22% | 14% | 18% | -8% |
| Other Income | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | -12 |
| Interest | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 6 | 2 |
| Depreciation | 2 | 3 | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 2 |
| Profit before tax | -2 | -2 | -1 | 2 | -2 | -4 | 0 | 2 | -1 | 0 | -18 |
| Tax % | 0% | 17% | 23% | 28% | 7% | -13% | -167% | 14% | 37% | -400% | 0% |
| Net Profit | -2 | -2 | -1 | 1 | -2 | -4 | 0 | 2 | -1 | 0 | -18 |
| EPS in Rs | -0.86 | -0.75 | -0.46 | 0.48 | -0.72 | -1.54 | 0.19 | 0.62 | -0.59 | 0.10 | -7.30 |
Last Updated: December 27, 2025, 1:32 pm
Below is a detailed analysis of the quarterly data for Cian Healthcare Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Sales, as of Sep 2024, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 62.00 Cr. (Mar 2024) to 19.00 Cr., marking a decrease of 43.00 Cr..
- For Expenses, as of Sep 2024, the value is 20.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 51.00 Cr. (Mar 2024) to 20.00 Cr., marking a decrease of 31.00 Cr..
- For Operating Profit, as of Sep 2024, the value is -1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 11.00 Cr. (Mar 2024) to -1.00 Cr., marking a decrease of 12.00 Cr..
- For OPM %, as of Sep 2024, the value is -8.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2024) to -8.00%, marking a decrease of 26.00%.
- For Other Income, as of Sep 2024, the value is -12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2024) to -12.00 Cr., marking a decrease of 12.00 Cr..
- For Interest, as of Sep 2024, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Sep 2024, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 3.00 Cr..
- For Profit before tax, as of Sep 2024, the value is -18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2024) to -18.00 Cr., marking a decrease of 18.00 Cr..
- For Tax %, as of Sep 2024, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -400.00% (Mar 2024) to 0.00%, marking an increase of 400.00%.
- For Net Profit, as of Sep 2024, the value is -18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2024) to -18.00 Cr., marking a decrease of 18.00 Cr..
- For EPS in Rs, as of Sep 2024, the value is -7.30. The value appears to be declining and may need further review. It has decreased from 0.10 (Mar 2024) to -7.30, marking a decrease of 7.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 57 | 74 | 78 | 69 | 62 | 31 |
| Expenses | 50 | 62 | 74 | 56 | 51 | 37 |
| Operating Profit | 7 | 12 | 4 | 13 | 11 | -7 |
| OPM % | 13% | 16% | 6% | 19% | 18% | -21% |
| Other Income | 1 | 0 | 0 | 1 | 0 | -12 |
| Interest | 7 | 8 | 7 | 6 | 6 | 3 |
| Depreciation | 4 | 3 | 4 | 5 | 5 | 4 |
| Profit before tax | -4 | 1 | -6 | 2 | 0 | -26 |
| Tax % | 7% | 91% | -8% | -2% | -1,600% | -0% |
| Net Profit | -4 | 0 | -6 | 2 | 1 | -26 |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.34 | -10.39 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 133.33% | -50.00% | -2700.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% | -183.33% | -2650.00% |
Cian Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | -8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -43% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:38 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 25 | 25 | 25 | 25 |
| Reserves | 35 | 35 | 30 | 32 | 33 | 7 |
| Borrowings | 73 | 71 | 63 | 61 | 56 | 55 |
| Other Liabilities | 25 | 28 | 47 | 42 | 47 | 69 |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 156 |
| Fixed Assets | 39 | 37 | 50 | 45 | 39 | 35 |
| CWIP | 25 | 26 | 13 | 14 | 15 | 15 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 |
| Other Assets | 87 | 90 | 98 | 97 | 102 | 101 |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 156 |
Below is a detailed analysis of the balance sheet data for Cian Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
- For Reserves, as of Mar 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2024) to 7.00 Cr., marking a decrease of 26.00 Cr..
- For Borrowings, as of Mar 2025, the value is 55.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 56.00 Cr. (Mar 2024) to 55.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 69.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 47.00 Cr. (Mar 2024) to 69.00 Cr., marking an increase of 22.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 156.00 Cr.. The value appears to be improving (decreasing). It has decreased from 161.00 Cr. (Mar 2024) to 156.00 Cr., marking a decrease of 5.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Mar 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 15.00 Cr..
- For Investments, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
- For Other Assets, as of Mar 2025, the value is 101.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2024) to 101.00 Cr., marking a decrease of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 161.00 Cr. (Mar 2024) to 156.00 Cr., marking a decrease of 5.00 Cr..
However, the Borrowings (55.00 Cr.) are higher than the Reserves (7.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -66.00 | -59.00 | -59.00 | -48.00 | -45.00 | -62.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Debtor Days | 127.80 | 93.56 | 125.24 | 139.58 | 121.15 |
| Inventory Days | 267.18 | 312.78 | 299.94 | 399.93 | 485.99 |
| Days Payable | 220.03 | 209.37 | 270.46 | 295.80 | 371.29 |
| Cash Conversion Cycle | 174.95 | 196.98 | 154.73 | 243.71 | 235.85 |
| Working Capital Days | 14.77 | 16.14 | 38.30 | 40.66 | 26.27 |
| ROCE % | 6.78% | 0.50% | 6.91% | 5.22% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -10.39 | 0.10 | 0.81 | -2.32 | 0.02 |
| Diluted EPS (Rs.) | -10.39 | 0.10 | 0.81 | -2.32 | 0.02 |
| Cash EPS (Rs.) | -8.63 | 2.29 | 2.98 | -0.50 | 1.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 12.95 | 23.10 | 23.00 | 22.19 | 24.92 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 12.95 | 23.10 | 23.00 | 22.19 | 24.93 |
| Revenue From Operations / Share (Rs.) | 12.32 | 24.68 | 27.44 | 31.15 | 31.56 |
| PBDIT / Share (Rs.) | -2.57 | 4.52 | 5.20 | 1.91 | 5.17 |
| PBIT / Share (Rs.) | -4.33 | 2.34 | 3.03 | 0.20 | 3.69 |
| PBT / Share (Rs.) | -10.40 | 0.01 | 0.79 | -2.37 | 0.38 |
| Net Profit / Share (Rs.) | -10.39 | 0.10 | 0.81 | -2.21 | 0.02 |
| NP After MI And SOA / Share (Rs.) | -10.39 | 0.10 | 0.81 | -2.21 | 0.02 |
| PBDIT Margin (%) | -20.89 | 18.32 | 18.94 | 6.14 | 16.37 |
| PBIT Margin (%) | -35.15 | 9.46 | 11.03 | 0.65 | 11.69 |
| PBT Margin (%) | -84.40 | 0.07 | 2.90 | -7.61 | 1.21 |
| Net Profit Margin (%) | -84.34 | 0.41 | 2.95 | -7.10 | 0.07 |
| NP After MI And SOA Margin (%) | -84.34 | 0.41 | 2.95 | -7.10 | 0.07 |
| Return on Networth / Equity (%) | -80.28 | 0.44 | 3.53 | -9.97 | 0.09 |
| Return on Capital Employeed (%) | -26.04 | 6.14 | 7.94 | 0.53 | 8.66 |
| Return On Assets (%) | -16.64 | 0.15 | 1.26 | -3.33 | 0.03 |
| Long Term Debt / Equity (X) | 0.21 | 0.47 | 0.51 | 0.68 | 0.64 |
| Total Debt / Equity (X) | 1.70 | 0.96 | 1.06 | 1.14 | 1.22 |
| Asset Turnover Ratio (%) | 0.19 | 0.38 | 0.44 | 0.43 | 0.49 |
| Current Ratio (X) | 0.61 | 1.09 | 1.14 | 1.14 | 1.10 |
| Quick Ratio (X) | 0.39 | 0.46 | 0.57 | 0.56 | 0.56 |
| Inventory Turnover Ratio (X) | 0.91 | 1.59 | 0.96 | 1.24 | 1.54 |
| Interest Coverage Ratio (X) | -2.21 | 1.95 | 2.28 | 0.74 | 1.56 |
| Interest Coverage Ratio (Post Tax) (X) | -3.71 | 1.04 | 1.34 | 0.15 | 1.03 |
| Enterprise Value (Cr.) | 45.84 | 106.16 | 129.47 | 109.32 | 94.69 |
| EV / Net Operating Revenue (X) | 1.49 | 1.72 | 1.89 | 1.40 | 1.28 |
| EV / EBITDA (X) | -7.12 | 9.39 | 9.96 | 22.84 | 7.84 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.83 | 1.02 | 0.61 | 0.35 |
| Price / BV (X) | 0.26 | 0.89 | 1.22 | 0.85 | 0.45 |
| Price / Net Operating Revenue (X) | 0.28 | 0.83 | 1.02 | 0.61 | 0.35 |
| EarningsYield | -3.01 | 0.00 | 0.02 | -0.11 | 0.00 |
After reviewing the key financial ratios for Cian Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -10.39. This value is below the healthy minimum of 5. It has decreased from 0.10 (Mar 24) to -10.39, marking a decrease of 10.49.
- For Diluted EPS (Rs.), as of Mar 25, the value is -10.39. This value is below the healthy minimum of 5. It has decreased from 0.10 (Mar 24) to -10.39, marking a decrease of 10.49.
- For Cash EPS (Rs.), as of Mar 25, the value is -8.63. This value is below the healthy minimum of 3. It has decreased from 2.29 (Mar 24) to -8.63, marking a decrease of 10.92.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.95. It has decreased from 23.10 (Mar 24) to 12.95, marking a decrease of 10.15.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.95. It has decreased from 23.10 (Mar 24) to 12.95, marking a decrease of 10.15.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 12.32. It has decreased from 24.68 (Mar 24) to 12.32, marking a decrease of 12.36.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -2.57. This value is below the healthy minimum of 2. It has decreased from 4.52 (Mar 24) to -2.57, marking a decrease of 7.09.
- For PBIT / Share (Rs.), as of Mar 25, the value is -4.33. This value is below the healthy minimum of 0. It has decreased from 2.34 (Mar 24) to -4.33, marking a decrease of 6.67.
- For PBT / Share (Rs.), as of Mar 25, the value is -10.40. This value is below the healthy minimum of 0. It has decreased from 0.01 (Mar 24) to -10.40, marking a decrease of 10.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -10.39. This value is below the healthy minimum of 2. It has decreased from 0.10 (Mar 24) to -10.39, marking a decrease of 10.49.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -10.39. This value is below the healthy minimum of 2. It has decreased from 0.10 (Mar 24) to -10.39, marking a decrease of 10.49.
- For PBDIT Margin (%), as of Mar 25, the value is -20.89. This value is below the healthy minimum of 10. It has decreased from 18.32 (Mar 24) to -20.89, marking a decrease of 39.21.
- For PBIT Margin (%), as of Mar 25, the value is -35.15. This value is below the healthy minimum of 10. It has decreased from 9.46 (Mar 24) to -35.15, marking a decrease of 44.61.
- For PBT Margin (%), as of Mar 25, the value is -84.40. This value is below the healthy minimum of 10. It has decreased from 0.07 (Mar 24) to -84.40, marking a decrease of 84.47.
- For Net Profit Margin (%), as of Mar 25, the value is -84.34. This value is below the healthy minimum of 5. It has decreased from 0.41 (Mar 24) to -84.34, marking a decrease of 84.75.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -84.34. This value is below the healthy minimum of 8. It has decreased from 0.41 (Mar 24) to -84.34, marking a decrease of 84.75.
- For Return on Networth / Equity (%), as of Mar 25, the value is -80.28. This value is below the healthy minimum of 15. It has decreased from 0.44 (Mar 24) to -80.28, marking a decrease of 80.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is -26.04. This value is below the healthy minimum of 10. It has decreased from 6.14 (Mar 24) to -26.04, marking a decrease of 32.18.
- For Return On Assets (%), as of Mar 25, the value is -16.64. This value is below the healthy minimum of 5. It has decreased from 0.15 (Mar 24) to -16.64, marking a decrease of 16.79.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.47 (Mar 24) to 0.21, marking a decrease of 0.26.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.70. This value exceeds the healthy maximum of 1. It has increased from 0.96 (Mar 24) to 1.70, marking an increase of 0.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has decreased from 0.38 (Mar 24) to 0.19, marking a decrease of 0.19.
- For Current Ratio (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1.5. It has decreased from 1.09 (Mar 24) to 0.61, marking a decrease of 0.48.
- For Quick Ratio (X), as of Mar 25, the value is 0.39. This value is below the healthy minimum of 1. It has decreased from 0.46 (Mar 24) to 0.39, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 4. It has decreased from 1.59 (Mar 24) to 0.91, marking a decrease of 0.68.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.21. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 24) to -2.21, marking a decrease of 4.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3.71. This value is below the healthy minimum of 3. It has decreased from 1.04 (Mar 24) to -3.71, marking a decrease of 4.75.
- For Enterprise Value (Cr.), as of Mar 25, the value is 45.84. It has decreased from 106.16 (Mar 24) to 45.84, marking a decrease of 60.32.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.49. This value is within the healthy range. It has decreased from 1.72 (Mar 24) to 1.49, marking a decrease of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is -7.12. This value is below the healthy minimum of 5. It has decreased from 9.39 (Mar 24) to -7.12, marking a decrease of 16.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.83 (Mar 24) to 0.27, marking a decrease of 0.56.
- For Price / BV (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has decreased from 0.89 (Mar 24) to 0.26, marking a decrease of 0.63.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.83 (Mar 24) to 0.28, marking a decrease of 0.55.
- For EarningsYield, as of Mar 25, the value is -3.01. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -3.01, marking a decrease of 3.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cian Healthcare Ltd:
- Net Profit Margin: -84.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -26.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -80.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3.71
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.39
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.7
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -84.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Milkat No. 3339, Block No.1, From South Side, Pune Maharashtra 412308 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suraj Shriniwas Zanwar | Managing Director |
| Mr. Sunil Kumar | Independent Director |
| Mr. Santosh Shivaji Pimparkar | Independent Director |
FAQ
What is the intrinsic value of Cian Healthcare Ltd?
Cian Healthcare Ltd's intrinsic value (as of 12 January 2026) is ₹48.21 which is 828.90% higher the current market price of ₹5.19, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹13.0 Cr. market cap, FY2025-2026 high/low of ₹7.66/2.97, reserves of ₹7 Cr, and liabilities of ₹156 Cr.
What is the Market Cap of Cian Healthcare Ltd?
The Market Cap of Cian Healthcare Ltd is 13.0 Cr..
What is the current Stock Price of Cian Healthcare Ltd as on 12 January 2026?
The current stock price of Cian Healthcare Ltd as on 12 January 2026 is ₹5.19.
What is the High / Low of Cian Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cian Healthcare Ltd stocks is ₹7.66/2.97.
What is the Stock P/E of Cian Healthcare Ltd?
The Stock P/E of Cian Healthcare Ltd is .
What is the Book Value of Cian Healthcare Ltd?
The Book Value of Cian Healthcare Ltd is 13.0.
What is the Dividend Yield of Cian Healthcare Ltd?
The Dividend Yield of Cian Healthcare Ltd is 0.00 %.
What is the ROCE of Cian Healthcare Ltd?
The ROCE of Cian Healthcare Ltd is 10.6 %.
What is the ROE of Cian Healthcare Ltd?
The ROE of Cian Healthcare Ltd is 30.3 %.
What is the Face Value of Cian Healthcare Ltd?
The Face Value of Cian Healthcare Ltd is 10.0.